Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas

Kazushige Adachi, Kayo Takahashi, Koji Nakamura, Akiko Otake, Naoko Sasamoto, Yukari Miyoshi, Mitsunori Shioji, Yoshimitsu Yamamoto, Mayumi Fujitani, Akinori Wakimoto, A. Wakimoto, Atsushi Tokuhira, Eiji Kobayashi, Akihiko Yoshimura, Kenjiro Sawada, Tadashi Kimura
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2016 · vol. 32(8) , pp. 646–649 · doi:10.3109/09513590.2016.1147547 · PMID:26890948 · W2289043567
article OA: closed CC0 ⤵ 34 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study evaluated dienogest's effect on ovarian endometrioma recurrence and pain after surgery, finding no recurrences and greater pain reduction in the dienogest group compared to expectant management.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

To assess the effect of dienogest on recurrence of ovarian endometriomas and severity of pain after laparoscopic surgery, a retrospective study of 81 patients was performed at three institutions in Osaka, Japan. Patients had a six-month minimum follow-up after laparoscopic surgery for ovarian endometriomas performed between June 2012 and August 2014. Patients who chose to receive 2 mg dienogest daily and those who were managed expectantly postoperatively were included. Recurrence was defined as the presence of endometriomas of more than 2 cm. A visual analog scale (VAS) was used to score the intensity of pelvic pain. The cumulative recurrence rate and absolute VAS score changes between the baseline and at 6, 12, 18 and 24 months after the start of administration were evaluated in both groups. The recurrence rate was 16.5% and 24.0% in the expectant management group at 12 and 24 months, respectively. No recurrences occurred in the dienogest treatment group. The rate of VAS score reduction was significantly higher in the dienogest than in the expectant management group. Dienogest is effective on the recurrence of ovarian endometrioma and relieving pelvic pain after laparoscopic surgery.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

mesh:D004715mesh:D017699endometrioma

MeSH descriptors

Endometriosis Hormone Antagonists Nandrolone Outcome Assessment, Health Care Ovarian Diseases Pelvic Pain Adult Disease-Free Survival Endometriosis Endometriosis Endometriosis Female Follow-Up Studies Hormone Antagonists Hormone Antagonists Humans Japan Laparoscopy Nandrolone Nandrolone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

Cited by (34)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:21:13.485820+00:00
License: CC0 · commercial use OK